A Phase I Trial of Intraperitoneal Mesothelin-Targeted CAR T Cell Therapy in Patients With Mesothelin-Positive Esophagogastric Adenocarcinoma With Peritoneal Carcinomatosis or Malignant Peritoneal Mesothelioma | Arctuva